Short Interest in Immunic, Inc. (NASDAQ:IMUX) Expands By 11.3%

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 2,470,000 shares, a growth of 11.3% from the February 29th total of 2,220,000 shares. Based on an average daily volume of 977,100 shares, the days-to-cover ratio is currently 2.5 days.

Immunic Stock Performance

NASDAQ IMUX traded up $0.04 during mid-day trading on Monday, reaching $1.36. 236,767 shares of the stock were exchanged, compared to its average volume of 1,005,387. Immunic has a 1-year low of $0.95 and a 1-year high of $3.11. The business's fifty day simple moving average is $1.30 and its 200 day simple moving average is $1.28. The stock has a market capitalization of $122.30 million, a PE ratio of -0.62 and a beta of 2.07.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.48) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.03. On average, analysts anticipate that Immunic will post -1 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Immunic from a "hold" rating to a "sell" rating in a research report on Friday.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. LPL Financial LLC acquired a new position in shares of Immunic in the 2nd quarter valued at about $28,000. American Century Companies Inc. bought a new stake in shares of Immunic during the 3rd quarter worth about $31,000. JPMorgan Chase & Co. raised its holdings in shares of Immunic by 1,143.9% in the 4th quarter. JPMorgan Chase & Co. now owns 24,903 shares of the company's stock worth $35,000 after purchasing an additional 22,901 shares in the last quarter. Two Sigma Securities LLC bought a new stake in shares of Immunic in the 2nd quarter worth approximately $36,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Immunic in the 1st quarter worth approximately $37,000. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.